

**CAFFEINE AND ADENOSINE A_{2A} RECEPTOR INACTIVATION DECREASE
STRIATAL NEUROPATHOLOGY IN A LENTIVIRAL-BASED MODEL OF
MACHADO-JOSEPH DISEASE**

Running head: Caffeine alleviates MJD-striatal neuropathology

Nélio Gonçalves, MSc ^{1,2}, Ana T. Simões, MSc ^{1,2}, Rodrigo A. Cunha, PhD ^{1,3}, Luís Pereira de Almeida, PhD ^{1,2}

From the ¹CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal; ² FFUC - Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal; ³FMUC - Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal

Address correspondence to Luís Pereira de Almeida, CNC -Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal. Ph: +351 239820190, Fax: +351 239822776; e-mail: luispa@ci.uc.pt.

Number of characters: Title: 135 Running head: 47

Number of words: Abstract: 253; Body text: 4019

Number of figures: 6 Number of coloured figures: 6 Number of tables: 2

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/ana.23866

Abstract**Objective:**

Machado-Joseph disease (MJD) is a neurodegenerative disorder associated with an abnormal CAG expansion, which translates into an expanded polyglutamine tract within ataxin-3. There is no therapy to prevent or modify disease progression. Since caffeine (a non-selective adenosine receptor antagonist) and selective adenosine A_{2A} receptor ($A_{2A}R$) blockade alleviate neurodegeneration in different brain diseases, namely at early stages of another polyglutamine-related disorders such as Huntington's disease, we now tested their ability to control MJD-associated neurodegeneration.

Methods:

MJD was modelled by transducing the striatum of male adult C57Bl6 mice with lentiviral vectors encoding mutant ataxin-3 in one hemisphere and wild-type ataxin-3 in the other hemisphere (as internal control). Caffeine (1 g/L) was applied through the drinking water. Mice were killed at different time points (from 2-12 weeks) to probe for the appearance of different morphological changes using immunohistochemical analysis.

Results:

Mutant ataxin-3 caused an evolving neuronal dysfunction (loss of DARPP-32 staining) leading to neurodegeneration (Cresyl violet and NeuN staining) associated with increased number of mutant ataxin-3 inclusions in the basal ganglia. Notably, mutant ataxin-3 triggered early synaptotoxicity (decreased synaptophysin and MAP-2 staining) and reactive gliosis (GFAP and CD11b staining), which predated neuronal dysfunction and damage. Caffeine reduced the appearance of all these morphological modifications, which were also abrogated in mice with a global $A_{2A}R$ inactivation (knockout).

Interpretation:

Our findings provide a demonstration that synaptotoxicity and gliosis are precocious events in MJD and that caffeine and $A_{2A}R$ inactivation decrease MJD-associated striatal pathology, which paves the way to consider $A_{2A}R$ as novel therapeutic targets to manage MJD.

Introduction

Various inherited neurodegenerative diseases result from an increase in the number of CAG codon repeats within the open reading frame of the responsible gene.¹ Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3, is one such dominantly-inherited polyglutamine neurodegenerative disease and the most common among ataxias.² It is characterised by an adult age of onset causing premature death associated with unstable expansion of a CAG stretch (over 55 repeats) in the *MJD1* gene that encodes a polyglutamine repeat in the corresponding ataxin-3 protein.^{3,4} The clinical hallmarks of MJD include progressive ataxia, dysfunction of motor coordination, postural instability and Parkinsonism among other symptoms.^{5,6} The neuropathology of MJD involves multiple systems such as cerebellar systems, substantia nigra and cranial nerve motor nuclei,^{3,7} as well as the striatum.⁸⁻¹¹ Degeneration and loss of neuronal cells in MJD is accompanied by the presence of protein aggregates,¹² designated as neuronal intranuclear inclusion bodies (NIIs). Although transgenic animal models closely mimicking the human pathology,^{8,13-15} have bolstered our understanding of MJD, the mechanisms accounting for neuronal degeneration are still largely unknown. Albeit not yet explored in MJD, studies in other polyQ disorders suggest that neuronal dysfunction and synaptotoxicity may precede degeneration and appearance of clinical symptoms,^{16,17} and that neuroinflammation,¹⁸ may function as an amplificatory loop exacerbating neuronal damage.¹⁹⁻²¹

There is currently no therapy to manage MJD. We posed that chronic caffeine consumption, which affords neuroprotection through the antagonism of adenosine A_{2A} receptors ($A_{2A}R$),²² might be a candidate strategy to manage MJD neurodegeneration. Caffeine and $A_{2A}R$ blockade afford robust neuroprotection in different neurodegenerative disorders, in accordance with the key role of $A_{2A}R$ s controlling synaptic viability, apoptotic neuronal death, astrocytic function and neuroinflammation.^{23,24} In particular, in Huntington's disease, another polyQ disorder, $A_{2A}R$ blockade at the prodrome or early stages of the disease seems to delay the appearance of clinical symptoms, mainly through a normalization

of striatal glutamatergic transmission, which impedes the characteristic degeneration of striatal neurons.²⁵ Importantly, it has recently been shown in induced pluripotent stem cell-derived neurons that glutamate overstimulation raises intracellular calcium levels activating the cysteine proteases calpains and promoting the proteolysis and aggregation of ataxin-3.²⁶ Moreover, calpain-mediated proteolysis of ataxin-3 in a rodent model of MJD mediates translocation of ataxin-3 to the cell nucleus, aggregation and neurodegeneration, which can be prevented by calpain inhibition.²⁷

In view of this proposed key role of glutamate overstimulation in MJD, we now investigated the time course of neuropathological modifications in a genetic model of MJD and tested the novel hypothesis that the manipulation of A_{2A}R function might also be beneficial in MJD.

Materials and Methods

Animals

Male C57BL/6 mice (Charles River, Barcelona, Spain) were housed and kept under a conventional 12-h light-dark cycle maintained on a temperature-controlled room with food and water provided *ad libitum* and used at 7 weeks of age. C57BL/6-background A_{2A}R knockout (A_{2A}R KO) and age-matched wild type control mice were obtained from parallel breeding of our colony of A_{2A}R KO mice, initially obtained from J.F.Chen (Boston University).²⁸ The experiments were carried out in accordance with the European Community directive (86/609/EEC) for the care and use of laboratory animals.

Drug treatment

We chose the dose of caffeine (1 g/L) administered through the drinking water, as a maximally effective and non-toxic dose, which we have previously shown to result in a plasma concentration of 50 μM,²⁹ and similar concentration in the brain parenchyma,³⁰ corresponding to a diary human consumption of circa 5 cups of coffee. Treatment with caffeine was begun 3 weeks before viral delivery onwards, since we have previously

reported that a minimum period of 2 weeks is required to allow a metabolic stabilization after beginning the free access to caffeine drinking.^{29, 31}

Viral vectors production

Lentiviral vectors encoding human wild-type ataxin-3 (atx3-27Q) or mutant ataxin-3 (atx3-72Q),⁸ were produced in 293T cells with a four-plasmid system, as previously described.³² The lentiviral particles were resuspended in 1% bovine serum albumin in phosphate-buffered saline (PBS). The viral particle content of batches was determined by assessing HIV-1 p24 antigen levels (RETROtek, Gentaur, Paris, France). Viral stocks were stored at -80°C until use.

In vivo injection into the striatum

Concentrated viral stocks were thawed on ice. After anesthesia of the mice with avertin (12 µL/g, i.p.), lentiviral vectors encoding human wild-type (atx3-27Q) or mutant ataxin-3 (atx3-72Q) were stereotaxically injected into the striatum in the following coordinates: antero-posterior: +0,6mm; lateral: ±1,8mm; ventral: -3,3mm; tooth bar: 0, which corresponds to the internal capsule, a large fiber tract passing through the middle of the striatum dividing both dorso-ventral and medial-lateral structures. Wild-type and A_{2A}R KO mice received 2 µL injections of lentivirus (200'000 ng of p24/mL) in each hemisphere, administering mutated ataxin-3 (atx3-72Q) in the right hemisphere and control wild type ataxin-3 (atx3-27Q) in the left hemisphere. Different groups of mice were kept in their home cages for different periods ranging from 2, 4, 8 and 12 weeks, before being killed for immunohistochemical analysis of morphological and neurochemical changes in the striatum.

Immunohistochemical procedure

After an overdose of avertin (2.5x 12 µL/g, i.p.), transcardiac perfusion of the mice was performed with PBS followed by fixation with 4% paraformaldehyde. The brains were then removed and post-fixed in 4% paraformaldehyde for 24h and cryoprotected by incubation in 25% sucrose/ phosphate buffer for 48h. The brains were frozen and 25 µm coronal sections

were cut using a cryostat (LEICA CM3050 S, Heidelberg, Germany) at -21°C . Slices throughout the entire striatum were collected in anatomical series and stored in 48-well trays as free-floating sections in PBS supplemented with $0.05\ \mu\text{M}$ sodium azide. The trays were stored at 4°C until immunohistochemical processing.

Sections were processed overnight at 4°C with the following primary antibodies: a mouse monoclonal anti-ataxin-3 antibody (1H9; 1:5000; Chemicon, Temecula, CA), a rabbit anti-DARPP-32 antibody (1:1000; Chemicon), or a mouse anti-NeuN antibody (1:1000; Chemicon) followed by 2h incubation at room temperature (RT) with the respective biotinylated secondary antibodies (1:200; Vector Laboratories, Burlingame, CA). Bound antibodies were visualized using the Vectastain ABC kit, with 3,3'-diaminobenzidine tetrahydrochloride (DAB metal concentrate; Pierce, Burlingame, CA) as substrate.

Triple staining for synaptophysin (rabbit polyclonal, 1:300; Chemicon) and MAP2 (mouse monoclonal AP20, 1:500; Santa Cruz Biotechnology, Santa Cruz, CA), GFAP (rabbit polyclonal, 1:1000; DAKO, Glostrup, Denmark) and CD11b (rat monoclonal 5C6, 1:500; AbD Serotec, Oxford, UK) together with DAPI (Sigma, St. Louis, MO) were performed. Free-floating sections were kept at RT for 2h in PBS with 0.1% Triton X-100 containing 10% normal goat serum (Gibco-Invitrogen, Barcelona, Spain), then overnight at 4°C in blocking solution with the primary antibodies. Sections were washed three times and incubated for 2h at RT with the corresponding secondary antibodies coupled to fluorophores goat anti-mouse or goat anti-rabbit or goat anti-rat Alexa Fluor 488 or Alexa Fluor 594 (1:200; Molecular Probes – Invitrogen, Eugene, OR) diluted in the blocking solution. The sections were washed three times and then mounted in mowiol Reagent (Sigma) on microscope slides.

Definition and analysis of protein immunoreactivities were made from the striatal center (site of injection) to the medial-lateral and dorsal-ventral striatal periphery from the needle tract. This disease model is based on the intra-striatal injection of lentivirus, which triggers physiological alterations evolving over time radially. Therefore, comparable striatal sections

between animals were defined from the site of injection in both rostral and caudal directions, using the needle tract due to the surgical procedure as reference-point.

Staining was visualized using Zeiss Axioskop 2 plus, Zeiss Axiovert 200 or Zeiss LSM 510 Meta imaging microscopes (Carl Zeiss Microimaging, Germany) equipped with AxioCam HR color digital cameras (Carl Zeiss Microimaging) and 5X, 20X, 40X and 63X Plan-Neofluar or a 63X Plan/Apochromat objectives and using the AxioVision 4.7 software package (Carl Zeiss Microimaging). Quantitative analysis of fluorescence was performed with a semi-automated image-analysis software package (Image J software, NIH, USA).

Cresyl violet staining

Coronal sections were pre-mounted and stained with cresyl violet for 45 sec, differentiated in 70% ethanol, dehydrated by passing twice through 95% ethanol, 100% ethanol and xylene solutions, and mounted onto microscope slides with Eukitt® (Sigma).

Evaluation of the volume of the DARPP-32 depleted volume and optic density

The extent of ataxin-3 lesions in the striatum was analyzed by photographing, with a x1.25 objective, 8 sections stained with DARPP-32 per animal (25 μ m thick sections at 200 μ m intervals), selected so as to obtain complete rostro-caudal sampling of the striatum, and by quantifying the area of the lesion with a semi-automated image-analysis software package (Image J software). The volume was then estimated with the following formula: volume = $d(a_1+a_2+a_3 \dots)$, where d is the distance between serial sections (200 μ m) and $a_1+a_2+a_3$ are DARPP-32-depleted areas for individual serial sections. The average grey value of all pixels measured in the lesioned area was recorded for each depleted area. Results are expressed as index of immunoreactivity of DARPP-32 considering unlesioned striatal area as 100% immunoreactivity.

Cell counts of ataxin-3 inclusions

Coronal sections showing complete rostro-caudal sampling (1 of 8 sections) of the striatum were scanned with a x20 objective. The analyzed areas of the striatum

encompassed the entire region containing ataxin-3 inclusions, as revealed by staining with the anti-ataxin-3 antibody. All inclusions were manually counted using a semi-automated image-analysis software package (Image J software).

Statistical analysis

Statistical comparisons were performed using either an unpaired Student's *t* test or one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison post hoc test. Results are expressed as mean \pm standard error of the mean (SEM). Significance thresholds were set at $p < 0.05$, $p < 0.01$ or $p < 0.001$, as defined in the text.

Results

Time course

We took advantage of using a lentiviral model of MJD to perform a temporal analysis of the relative appearance of different features from early dysfunction to late neuronal loss. Thus, we carried out a time-course study from 2 to 12 weeks upon lentiviral-mediated expression of wild-type and mutant ataxin-3, and we analysed different neuropathological features such as markers of synaptic loss, neuronal dysfunction, neuronal loss, of astrogliosis and microgliosis **as well as ataxin-3 inclusions**. Figure 1 summarises the temporal evolution of each of these changes, which will be further detailed below.

Neuronal degeneration and loss

In order to directly test if caffeine and $A_{2A}R$ inactivation indeed mitigate neurodegeneration, we first analyzed photomicrographs under bright field and then upon cresyl violet staining. Lentiviral-mediated expression of mutant ataxin-3 (LV-atx3-72Q) caused a clear condensation of the internal capsule attributable to striatal tissue shrinkage, which was evident in water-drinking mice at 12 weeks, but absent on bright-field sections of both caffeine-drinking animals and global $A_{2A}R$ knockout (KO) mice, as well as in the contralateral striatum challenged with wild-type ataxin-3 (LV-atx3-27Q) (Fig 2A). Cresyl violet staining revealed a marked reduction ($p < 0.05$) of the number of degenerated shrunken

hyperchromatic nuclei in caffeine-drinking mice **even though it remained considerably high**; the specificity of the effect over A_{2A}R was confirmed in A_{2A}R KO animals, which reproduced the alleviation of pathology observed in caffeine-treated animals ($p < 0.05$; Fig 2B and E).

To further investigate the neuroprotective effects of caffeine at a late time-point in this model of MJD, we evaluated the immunoreactivity of the neuronal nuclear marker NeuN. A clear loss of NeuN-stained neurons could be seen in the water-drinking group at 12 weeks after mutant ataxin-3 transduction, which was not detectable after wild-type ataxin-3 transduction, and was nearly absent in mutant ataxin-3-expressing animals upon caffeine treatment (Fig 2C).

These data suggest that there is a progression in the degeneration pattern in MJD-associated striatal pathology leading to loss of neuronal markers, which is reduced by chronic caffeine consumption as well as genetically deleting the A_{2A}R.

Neuronal functional modifications

Previous reports have indicated that striatal neuronal dysfunction may precede degeneration and appearance of clinical symptoms in MJD.³³ Additionally, DARPP-32 (dopamine and cAMP-regulated phosphoprotein) was previously shown to be a sensitive marker that allows immunohistochemical detection of this early neuronal dysfunction.^{8,27,34,35} Accordingly, DARPP-32 immunohistochemistry revealed a large depleted staining volume of $0.60 \pm 0.12 \text{ mm}^3$ ($n=5$) at 4 weeks post-injection of lentivirus encoding atx3-72Q in the water-drinking group whereas caffeine-treated animals exhibited significantly smaller dysfunctional volume ($0.21 \pm 0.06 \text{ mm}^3$ ($n=6$); $p < 0.05$) at this time-point. No loss of DARPP-32 immunoreactivity was detected upon LV-atx3-27Q injections (Fig 3A *upper panel* and B).

At higher magnification, analysis of the striatal DARPP-32-depleted area of water-drinking animals at 12 weeks after injection of lentiviral vectors encoding mutant ataxin-3 revealed that the DARPP-32-stained cell bodies and the corresponding tissue (internal capsule) were no longer present, originating a collapse of the tissue, which joins together

fiber patches (see arrows in Fig 3A *lower panel*). This fiber accumulation presumably results from neuronal degeneration, which was not observed in the caffeine-treated or in A_{2A}R KO mice challenged with mutant ataxin-3. Density analysis of DARPP-32 immunoreactivity (Table 1) showed a significant preservation of this marker in caffeine-treated ($p < 0.01$) and A_{2A}R KO groups ($p < 0.05$) at 12 weeks post-injection of lentivirus encoding atx3-72Q, as compared to the respective water-drinking groups.

These data suggest that both chronic caffeine consumption as well as the genetic deletion of A_{2A}R is able to reduce neuronal dysfunction in MJD.

Astrogliosis and microgliosis

Interestingly, the mutant ataxin-3-induced loss of NeuN immunoreactivity was accompanied by a local increase of GFAP immunoreactivity suggestive of astrocytic activation, which was nearly absent in caffeine-treated animals (Fig 2D). Since reactive gliosis is widely accepted to contribute to chronic neurodegenerative diseases, we further investigated if the blockade of A_{2A}R was able to prevent the increase of gliosis associated with MJD pathogenesis at an early time-point. The injection of lentiviral vectors encoding mutant ataxin-3 (LV-atx3-72Q) triggered a robust increase of GFAP immunoreactivity at 4 weeks when compared with the contralateral striatum challenged with wild-type ataxin-3 (LV-atx3-27Q) (Fig 4A). Notably, this GFAP immunoreactivity triggered by expression of mutated ataxin-3 was observed as early as 2 weeks (Fig 4B). Additionally, strong immunoreactivity for the microglial protein, cluster of differentiation molecule B11 (CD11b), was found at 4 weeks revealing microglial recruitment (Fig 4C), which was significantly and robustly reduced in caffeine-treated animals. This clearly establishes the presence of reactive gliosis in the striatum in this genetic model of MJD.

Importantly, treatment with caffeine (1 g/L), prevented both the astrogliosis (Fig 4A and B) and the putative microgliosis (Fig 4C) triggered by mutant ataxin-3 indicating that chronic caffeine consumption can prevent reactive gliosis associated with MJD.

Nuclear inclusions of mutant ataxin-3

Since microglia is well established to play a role in the seeding (through enhanced inflammatory status) and processing (through phagocytosis) of protein aggregates and the presence of ataxin-3 aggregates is one hallmark of MJD, we next tested the impact of caffeine and $A_{2A}R$ inactivation on the aggregation pattern of ataxin-3 by immunohistochemical staining. No aggregation was seen upon LV-atx3-27Q injection (Fig 5A) while a significant increase in the total number of mutant ataxin-3 nuclear inclusions was observed at 8 weeks post-injection of lentiviral vectors encoding mutant ataxin-3 in both caffeine-drinking wild type mice ($p < 0.05$) as well as in $A_{2A}R$ KO animals ($p < 0.05$) when compared to the respective water-drinking groups (Fig 5B and C). Interestingly, we previously demonstrated that at 8 weeks after lentiviral transduction there were 4 times higher striatal levels of mutant ataxin-3 than those of endogenous ataxin-3,⁸ although the levels were similar 4 weeks after lentiviral administration. This observation that caffeine or $A_{2A}R$ inactivation enhance even more the number of ataxin-3 inclusions while decreasing neurodegeneration is in agreement with the scenario that these inclusions may be a way to sequester the soluble and noxious forms of ataxin-3.

Synaptotoxicity

There is accumulating evidence that one of the earliest features of neurodegenerative diseases is the dysfunction and loss of synapses.^{24,36} Also, $A_{2A}R$ are synaptic receptors,³⁷ and $A_{2A}R$ blockade efficiently normalizes synaptic function and prevents synaptotoxicity in different animal models of brain diseases.²² Since synaptotoxicity has not been explored in models of MJD, we investigated whether synaptotoxicity was present in our lentiviral model of MJD and if this feature indeed preceded the appearance of ataxin-3 inclusions, neuronal dysfunction and overt neurodegeneration. This was carried out by immunohistochemical evaluation of two synaptic markers, synaptophysin (pre-synaptic protein) and microtubule-associated protein 2 (MAP-2, dendritic protein).

Density analysis of synaptophysin and MAP-2 immunoreactivities at 2 weeks post-injection (Table 2 and Fig 6) clearly showed a significant loss of both markers ($p < 0.001$) upon mutant ataxin-3 expression. No such early loss of either markers was observed in caffeine-drinking mice challenged with atx3-72Q, i.e. 2 weeks after insult or upon expression of wild-type ataxin-3 (data not shown). These data provide the first evidence that mutant ataxin-3 induces an early synaptotoxicity in the striatum, which is prevented by chronic caffeine consumption.

Discussion

In the present study, we carried out a temporal analysis of different features of brain dysfunction and damage in a genetic model of MJD and tested the impact of caffeine and adenosine $A_{2A}R$ ($A_{2A}R$) blockade thereupon. We provide the first evidence showing that: i) synaptotoxicity and gliosis in the striatum are early events predating neurodegeneration; ii) pharmacological and genetic manipulation of adenosine $A_{2A}R$ can delay MJD-associated striatal pathology.

Consistent with previous reports,^{8,13,14} lentiviral-mediated overexpression of mutant ataxin-3 in the mouse brain induced a clear neuronal dysfunction typified by loss of DARPP-32 immunoreactivity, and overt neurodegeneration, accompanied by an increased number of ataxin-3 inclusions. The present study also revealed two novel morphological features in this model of MJD, namely the loss of synaptic markers (synaptotoxicity) and reactive gliosis. Synaptotoxicity is in line with suggestions of axonal degeneration assessed by MRI,³⁸ and loss of dopaminergic terminals assessed by PET in MJD patients,¹¹ and with the presence of axonal inclusions in the human patient's brains,³⁹ as well as with the observed impact of mutant ataxin-3 on the cerebellar mRNA expression of proteins involved in synaptic transmission.⁴⁰ Notably, the present time course study provides direct evidence that this synaptotoxicity might be an early, hitherto unrecognized, feature of MJD. This is in notable agreement with the observations that another polyglutamine-related disease, namely Huntington's disease is characterized by early changes in synapses,^{41,42} to such an extent

that it has been proposed that Huntington's disease might actually be a synaptopathy.⁴³ Actually, it is worth noting that synaptotoxicity seems to be an early feature of different other neurodegenerative and neuropsychiatric diseases, strengthening the crucial role of synaptic impairment in the initiation of brain disorders.^{22,36,44} Since there is evidence that ataxin-3 is also located in axons and dendrites,⁴⁵ the present observation that synaptic changes are an early feature of MJD opens a new area of research on the putative role of ataxin-3 in the control of synaptic function and damage. In this context, the recent report that excitatory synaptic transmission can control the aggregation of mutant ataxin-3 adds a further dimension to the relation between MJD and synaptic activity.²⁶

The present time course study of striatal changes in this MJD model also revealed another under-appreciated morphological feature that predated neuronal dysfunction and damage, namely reactive gliosis. There has been episodic reports of astrogliosis and microgliosis, typified by changes in astrocytes and microglia morphology both in patients,⁴⁶ and in transgenic models of MJD,⁴⁷ as well as increased expression of cytokines and proinflammatory chemokines, which are compatible with mutant ataxin 3-induced changes in brain inflammatory mediators.⁴⁸ However, in keeping with the fact that our lentiviral-mouse model resulted in an overexpression of mutant ataxin-3 even in comparable levels to the endogenous form, the present report provides evidence that reactive astrogliosis might be an early feature in MJD, which is particularly relevant in view of the surge of interest in the role of non-neuronal brain cells in the aetiology of neurodegenerative disorders.⁴⁹ A putative role of glial cells in MJD is further heralded by evidence of the presence of ataxin-3 in glial cells.^{12,50} Again, this observation should open a novel area of research fostering a better understanding of the role of ataxin-3 in astrocytes and on the consequences of astrocytic adaptation upon accumulation of mutated ataxin-3.

Thus, the present time-course exploration of neuropathological features associated with this genetic model of MJD identifies synaptotoxicity and astrogliosis as precocious modifications followed by microgliosis and neuronal dysfunction, appearance of NfIs and

overt neuronal damage. This time course is in general agreement with the recognition that synaptotoxicity and astrocytic-related metabolic imbalance are amongst the most precocious modifications in different neurodegenerative disorders and that neuroinflammation, previously implicated in MJD,⁴⁸ may be a candidate process to mediate the spreading and amplification of damage until overt neuronal dysfunction and damage can be recorded.^{24,36,49}

The second prominent conclusion of this study is the demonstration that the chronic consumption of a reasonable dose of caffeine compatible to a significant blockade of adenosine effects on A_{2A} (most potent) and A₁ receptors⁵¹ or the genetic elimination of A_{2A}R mitigated the striatal neuropathological modifications caused by the expression of mutated ataxin-3. This is in agreement with the ability of A_{2A}R, mainly targeted by chronic caffeine consumption,^{22,52} to afford neuroprotection against different neurodegenerative disorders, namely Alzheimer's, Parkinson's or Huntington's disease.^{22,25,53} Notably, most of the compartments that we now showed to be affected in this genetic model of MJD are effectively normalized by A_{2A}R blockade in chronic brain diseases: thus, A_{2A}R blockade prevents synaptotoxicity,^{54,55} in accordance with the enrichment of A_{2A}R in synapses,³⁷ and also controls astrogliosis,⁵⁶⁻⁵⁸ and microgliosis,⁵⁹ striatal neurodegeneration,⁶⁰ and neuronal death.^{23,61} Accordingly, in our genetic model of MJD, chronic caffeine consumption or genetic deletion of A_{2A}R abrogated the loss of synaptic markers, prevented astrogliosis and microglia activation, reduced cell injury and striatal degeneration rescuing its normal cytoarchitecture. Therefore, this provides the first evidence that the manipulation of a neuromodulation system operated by A_{2A}R is effective in controlling the initial cascade of events triggered by the pathogenic ataxin-3 protein (synaptotoxicity and gliosis) that culminate in a reduced neuronal degeneration.

It is worth noting that this general neuroprotection afforded by caffeine and A_{2A}R blockade is accompanied by an accumulation of ataxin-3 aggregates into intracellular nuclear inclusions. The inverse correlation between the impact of caffeine and A_{2A}R blockade on mutant ataxin-3-induced NIs and neuropathology strongly suggests that the aggregation of

ataxin-3 could correspond to a cellular defensive mechanism against soluble, more toxic species,⁶²⁻⁶⁵ rather than being the main cause of degeneration. Therefore, although it cannot be excluded that this might result from a better neuronal survival in treated animals, we hypothesized that aggregates may be neuroprotective. Nevertheless, the neuroprotection conveyed by caffeine and A_{2A}R blockade might be of limited duration since the number of pycnotic nuclei remained relatively high.

The present exploration of the time course of MJD-associated neuropathological features and its modification by A_{2A}R provides a novel insight into the neuropathology of MJD but does not explore the underlying mechanistic processes. Ataxin-3 is a polyubiquitin-binding protein whose physiological function has been linked to de-ubiquitination,⁶⁶⁻⁶⁹ and MJD is argued to result from a toxic gain of function of mutant ataxin-3. In keeping with our proposal that synaptotoxicity might be a precocious modification in MJD, several studies highlight the importance of the ubiquitin-proteasome system (UPS) in synapses,^{70,71} namely in presynaptic terminals,^{72,73} where it is affected in other polyQ neurological diseases;⁷⁴ furthermore, there is preliminary evidence that A_{2A}Rs directly bind to UPS components,⁷⁵ and control the UPS activity,⁷⁶ paving the way for a putative direct control by A_{2A}R of synaptic UPS. The proposal that the ability of A_{2A}Rs to control another polyQ neurological disorder (Huntington's disease) depends on the control of glutamatergic transmission prompts an alternative mechanism by which the A_{2A}R-mediated control of the initial event in MJD might be related to the ability of A_{2A}R to control abnormal glutamatergic transmission through direct synaptic effects,⁷⁷ or indirectly through control of astrocytic glutamate uptake.^{78,79} Thus, albeit the molecular mechanism of A_{2A}R-mediated control of MJD remains to be determined, the present study provides new clues for particular compartments where such mechanisms should be explored.

In conclusion, the present study provides a novel insight into the pathology of MJD bringing to the centre stage synaptotoxicity and gliosis as precocious events in MJD. Furthermore, it provides the first realistic and safe promising life style prophylactic strategy to

delay the onset of this inherited disorder, based on the consumption of caffeine. Finally, it provides the first suggestion that A_{2A}R might be a novel therapeutic target to interfere with the inexorable evolution of this neurodegenerative disease.

Acknowledgements

This work was supported by Fundação para a Ciência e a Tecnologia (FCT), SAU-FCF/70384/2006, SAU-NEU/099307/2008, SAU-NEU/108668/2008, The Richard Chin and Lily Lock Machado Joseph disease Research Fund and the Association Française Contre les Myopathies (AFM). N.G. and A.T.S. were supported by FCT fellowships BD/33186/2007 and BD/38636/2007.

References

1. Koshy BT, Zoghbi HY. The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. *Brain Pathol.* 1997;7:927-942
2. Ranum LP, Lundgren JK, Schut LJ et al. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia. *Am J Hum Genet.* 1995;57:603-608
3. Durr A, Stevanin G, Cancel G et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. *Ann Neurol.* 1996;39:490-499
4. Kawaguchi Y, Okamoto T, Taniwaki M et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. *Nat Genet.* 1994;8:221-228
5. Gwinn-Hardy K, Singleton A, O'Suilleabhain P et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. *Arch Neurol.* 2001;58:296-299

6. Taroni F, DiDonato S. Pathways to motor incoordination: the inherited ataxias. *Nat Rev Neurosci.* 2004;5:641-655
7. Sudarsky L, Coutinho P. Machado-Joseph disease. *Clin Neurosci.* 1995;3:17-22
8. Alves S, Regulier E, Nascimento-Ferreira I et al. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. *Hum Mol Genet.* 2008;17:2071-2083
9. Klockgether T, Skalej M, Wedekind D et al. Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. *Brain.* 1998;121:1687-1693
10. Taniwaki T, Sakai T, Kobayashi T et al. Positron emission tomography (PET) in Machado-Joseph disease. *J Neurol Sci.* 1997;145:63-67
11. Wullner U, Reimold M, Abele M et al. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. *Arch Neurol.* 2005;62:1280-1285
12. Paulson HL, Perez MK, Trottier Y et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. *Neuron.* 1997;19:333-344
13. Bichelmeier U, Schmidt T, Hubener J et al. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. *J Neurosci.* 2007;27:7418-7428
14. Gotf D, Katzen SM, Mez J et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. *J Neurosci.* 2004;24:10266-10279
15. Cemal CK, Carroll CJ, Lawrence L et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. *Hum Mol Genet.* 2002;11:1075-1094
16. Andrews TC, Weeks RA, Turjanski N et al. Huntington's disease progression. PET and clinical observations. *Brain.* 1999;122:2353-2363

17. Li H, Li SH, Yu ZX et al. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. *J Neurosci*. 2001;21:8473-8481
18. Bantubungi K, Jacquard C, Greco A et al. Minocycline in phenotypic models of Huntington's disease. *Neurobiol Dis*. 2005;18:206-217
19. Aktas O, Smorodchenko A, Brocke S et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. *Neuron*. 2005;46:421-432
20. Gao HM, Kotzbauer PT, Uryu K et al. Neuroinflammation and oxidation/nitration of α -synuclein linked to dopaminergic neurodegeneration. *J Neurosci*. 2008;28:7687-7698
21. Lee JW, Lee YK, Yuk DY et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. *J Neuroinflammation*. 2008;5:37
22. Cunha RA, Agostinho PM. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. *J Alzheimers Dis*. 2010;20 Suppl 1:S95-S116
23. Chen JF, Sonsalla PK, Pedata F et al. Adenosine A_{2A} receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. *Prog Neurobiol*. 2007;83:310-331
24. Gomes CV, Kaster MP, Tome AR et al. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. *Biochim Biophys Acta*. 2011;1808:1380-1399
25. Popoli P, Blum D, Martire A et al. Functions, dysfunctions and possible therapeutic relevance of adenosine A_{2A} receptors in Huntington's disease. *Prog Neurobiol*. 2007;81:331-348
26. Koch P, Breuer P, Peitz M et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. *Nature*. 2011;480:543-546
27. Simões AT, Gonçalves N, Koeppen A et al. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin-3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. *Brain*. 2012;135:2428-2439

28. Chen JF, Huang Z, Ma J et al. A_{2A} adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. *J Neurosci*. 1999;19:9192-9200
29. Duarte JM, Agostinho PM, Carvalho RA, Cunha RA. Caffeine consumption prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of NONcZNO10/LTJ mice. *PLoS One*. 2012;7:e21899
30. Costenla AR, Cunha RA, de Mendonca A. Caffeine, adenosine receptors, and synaptic plasticity. *J Alzheimers Dis*. 2010;20 Suppl 1:S25-S34
31. Duarte JM, Carvalho RA, Cunha RA, Gruetter R. Caffeine consumption attenuates neurochemical modifications in the hippocampus of streptozotocin-induced diabetic rats. *J Neurochem*. 2009;111:368-379
32. de Almeida LP, Zala D, Aebischer P, Deglon N. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. *Neurobiol Dis*. 2001;8:433-446
33. Yen TC, Tzen KY, Chen MC et al. Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers. *J Nucl Med*. 2002;43:153-159
34. de Almeida LP, Ross CA, Zala D et al. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. *J Neurosci*. 2002;22:3473-3483
35. Cyr M, Beaulieu JM, Laakso A et al. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. *Proc Natl Acad Sci U S A*. 2003;100:11035-11040
36. Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. *Neurology*. 2004;63:1155-1162
37. Rebola N, Canas PM, Oliveira CR, Cunha RA. Different synaptic and subsynaptic localization of adenosine A_{2A} receptors in the hippocampus and striatum of the rat. *Neuroscience*. 2005;132:893-903

38. D'Abreu A, Franca M, Jr., Appenzeller S et al. Axonal dysfunction in the deep white matter in Machado-Joseph disease. *J Neuroimaging*. 2009;19:9-12
39. Seidel K, den Dunnen WF, Schultz C et al. Axonal inclusions in spinocerebellar ataxia type 3. *Acta Neuropathol*. 2010;120:449-460
40. Chou AH, Chen SY, Yeh TH et al. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. *Neurobiol Dis*. 2011;41:481-488
41. DiProspero NA, Chen EY, Charles V et al. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. *J Neurocytol*. 2004;33:517-533
42. Smith R, Klein P, Koc-Schmitz Y et al. Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease. *J Neurochem*. 2007;103:115-123
43. Li JY, Plomann M, Brundin P. Huntington's disease: a synaptopathy? *Trends Mol Med*. 2003;9:414-420
44. Wishart TM, Parson SH, Gillingwater TH. Synaptic vulnerability in neurodegenerative disease. *J Neuropathol Exp Neurol*. 2006;65:733-739
45. Trottier Y, Cancel G, An-Gourfinkel I et al. Heterogeneous intracellular localization and expression of ataxin-3. *Neurobiol Dis*. 1998;5:335-347
46. Horimoto Y, Matsumoto M, Akatsu H et al. Longitudinal study on MRI intensity changes of Machado-Joseph disease: correlation between MRI findings and neuropathological changes. *J Neurol*. 2011;258:1657-1664
47. Silva-Fernandes A, Costa Mdo C, Duarte-Silva S et al. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. *Neurobiol Dis*. 2010;40:163-176
48. Evert BO, Vogt IR, Kindermann C et al. Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains. *J Neurosci*. 2001;21:5389-5396

49. Lobsiger CS, Cleveland DW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. *Nat Neurosci.* 2007;10:1355-1360
50. Wang G, Ide K, Nukina N et al. Machado-Joseph disease gene product identified in lymphocytes and brain. *Biochem Biophys Res Commun.* 1997;233:476-479
51. Fredholm BB, Battig K, Holmen J et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol Rev.* 1999;51:83-133
52. Ferré S. An update on the mechanisms of the psychostimulant effects of caffeine. *J Neurochem.* 2008;105:1067-1079
53. Schwarzschild MA, Agnati L, Fuxe K et al. Targeting adenosine A_{2A} receptors in Parkinson's disease. *Trends Neurosci.* 2006;29:647-654
54. Canas PM, Porciuncula LO, Cunha GM et al. Adenosine A_{2A} receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. *J Neurosci.* 2009;29:14741-14751
55. Silva CG, Porciuncula LO, Canas PM et al. Blockade of adenosine A_{2A} receptors prevents staurosporine-induced apoptosis of rat hippocampal neurons. *Neurobiol Dis.* 2007;27:182-189
56. Brambilla R, Cottini L, Fumagalli M et al. Blockade of A_{2A} adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. *Glia.* 2003;43:190-194
57. Minghetti L, Greco A, Potenza RL et al. Effects of the adenosine A_{2A} receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. *J Neuropathol Exp Neurol.* 2007;66:363-371
58. Yu L, Shen HY, Coelho JE et al. Adenosine A_{2A} receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. *Ann Neurol.* 2008;63:338-346

59. Rebola N, Simões AP, Canas PM et al. Adenosine A_{2A} receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. *J Neurochem.* 2011;117:100-111
60. Schiffmann SN, Fisone G, Moresco R et al. Adenosine A_{2A} receptors and basal ganglia physiology. *Prog Neurobiol.* 2007;83:277-292
61. Cunha RA. Neuroprotection by adenosine in the brain: From A_1 receptor activation to A_{2A} receptor blockade. *Purinergic Signal.* 2005;1:111-134
62. Arrasate M, Mitra S, Schweitzer ES et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. *Nature.* 2004;431:805-810
63. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. *Cell.* 1998;95:55-66
64. Takahashi T, Kikuchi S, Katada S et al. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. *Hum Mol Genet.* 2008;17:345-356
65. Taylor JP, Tanaka F, Robitschek J et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. *Hum Mol Genet.* 2003;12:749-757
66. Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. *Hum Mol Genet.* 2003;12:3195-3205
67. Doss-Pepe EW, Stenroos ES, Johnson WG, Madura K. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. *Mol Cell Biol.* 2003;23:6469-6483
68. Kuhlbrodt K, Janiesch PC, Kevei E et al. The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and proteostasis. *Nat Cell Biol.* 2011;13:273-281

69. Warrick JM, Morabito LM, Bilen J et al. Ataxin-3 suppresses polyglutamine neurodegeneration in *Drosophila* by a ubiquitin-associated mechanism. *Mol Cell*. 2005;18:37-48
70. Cajigas IJ, Will T, Schuman EM. Protein homeostasis and synaptic plasticity. *EMBO J*. 2010;29:2746-2752
71. DiAntonio A, Hicke L. Ubiquitin-dependent regulation of the synapse. *Annu Rev Neurosci*. 2004;27:223-246
72. Jiang X, Litkowski PE, Taylor AA et al. A role for the ubiquitin-proteasome system in activity-dependent presynaptic silencing. *J Neurosci*. 2010;30:1798-1809
73. Rinetti GV, Schweizer FE. Ubiquitination acutely regulates presynaptic neurotransmitter release in mammalian neurons. *J Neurosci*. 2010;30:3157-3166
74. Wang J, Wang CE, Orr A et al. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. *J Cell Biol*. 2008;180:1177-1189
75. Milojevic T, Reiterer V, Stefan E et al. The ubiquitin-specific protease Usp4 regulates the cell surface level of the A_{2A} receptor. *Mol Pharmacol*. 2006;69:1083-1094
76. Chiang MC, Chen HM, Lai HL et al. The A_{2A} adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. *Hum Mol Genet*. 2009;18:2929-2942
77. Rebola N, Lujan R, Cunha RA, Mulle C. Adenosine A_{2A} receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. *Neuron*. 2008;57:121-134
78. Matos M, Augusto E, Santos-Rodrigues AD et al. Adenosine A_{2A} receptors modulate glutamate uptake in cultured astrocytes and gliosomes. *Glia*. 2012;60:702-716
79. Nishizaki T, Nagai K, Nomura T et al. A new neuromodulatory pathway with a glial contribution mediated via A_{2a} adenosine receptors. *Glia*. 2002;39:133-147

Figure Legends and Tables

Figure 1: Summary of the time-course of appearance of different morphological features in a lentiviral-based model of Machado-Joseph disease. Loss of synaptic markers and astrogliosis were amongst the most precocious morphological alteration, closely followed by microgliosis and neuronal dysfunction as well as increases of the number of ataxin-3 inclusions, whereas overt neuronal damage occurred later in the development of the disease. Microgliosis would probably be found at later time-points, however, that was not evaluated.

Figure 2: Caffeine treatment or A_{2A}R genetic depletion decreased cell injury and striatal degeneration. Representative bright-field photomicrographs and immunohistochemical stainings from around the injection site area at 12 weeks post-injection of the viral vectors encoding wild-type or mutant ataxin-3. (A) Coalescence of the internal capsule of the striatum was neither seen in the caffeine-treated group nor in the A_{2A}R KO animals. (B) Cresyl violet-stained sections showed a significant reduction of the number of striatal condensed nuclei upon mutant ataxin-3 transduction in the caffeine-treated group as well as in the A_{2A}R KO group relative to their respective water-drinking groups, as quantified in *panel E*. (C) A nearly absent loss of neuronal nuclei (NeuN) staining immunoreactivity was seen in the caffeine-treated group as well as in the A_{2A}R KO group. (D) GFAP immunoreactivity showed an increased accumulation of astrocytes (green) replacing neurons after injection of mutant ataxin-3, which was prevented by caffeine consumption. No morphological modifications were detected upon LV-atx3-27Q injections. Statistical significance was evaluated with Student's *t* test (**p* < 0.05) comparing both caffeine-drinking and A_{2A}R KO groups with their respective water-drinking wild-type groups upon LV-atx3-72Q injections.

Figure 3: Caffeine treatment or A_{2A}R genetic depletion reduced neuronal dysfunction. (A, *upper panel*) A large DARPP-32 depleted volume was observed 4 weeks after injection of the viral vectors encoding mutant ataxin-3 in the water-drinking group whereas caffeine-drinking mice exhibited a much smaller lesion area at this time-point. This is quantified in

panel B as depleted volume of DARPP-32 staining. No loss of DARPP-32 staining was observed upon LV-atx3-27Q injections. (A, *lower panel*) At higher magnification, 12 weeks exposure to mutated ataxin-3 revealed a clear condensation of the internal capsule, which joined together fiber patches (arrows). This fiber accumulation was not observed in the caffeine-treated animals or in $A_{2A}R$ KO mice. Statistical significance was evaluated with Student's *t* test ($*p < 0.05$) comparing caffeine-treated ($n=6$) with water-drinking animals ($n=5$).

Figure 4: Caffeine treatment decreased MJD-associated astroglial activation and prevented microglia recruitment. (A) Quantification analysis of GFAP immunoreactivity at 4 weeks post-injection of the viral vectors encoding wild-type or mutant ataxin-3. Caffeine abrogated astrocytic activation ($^{##}p < 0.01$) to the levels induced by wild-type ataxin-3 (internal control). (B) Caffeine consumption attenuated the mutant ataxin-3-induced activation of astrocytes, gauged by enhanced immunoreactivity of Glial Fibrillary Acidic Protein (GFAP, green) at an earlier time point: 2 weeks. (C) No immunoreactivity for activated microglia, CD11b (Ab 5C6, green), was observed 4 weeks after insult in the caffeine-treated group whereas it was present in water-drinking mice. Statistical significance was evaluated with Student's *t* test ($**p < 0.01$) comparing mutant ataxin-3 striatal hemisphere with the contralateral wild-type ataxin-3 hemisphere, and caffeine-drinking with water-drinking groups.

Figure 5: Caffeine treatment or $A_{2A}R$ genetic depletion significantly increased the total number of mutant ataxin-3 inclusions. (A) Using anti-ataxin-3 antibody (Ab 1H9), no nuclear inclusions of ataxin-3 were found on both wild-type and $A_{2A}R$ KO animals upon expression of wild-type ataxin-3. (B) A significant increase in the number of mutant ataxin-3 inclusions was observed 8 weeks post-injection of lentiviral vectors encoding mutant ataxin-3 either in caffeine-treated ($n=5$) or $A_{2A}R$ KO ($n=5$) mice compared to the respective water-drinking wild-type animals transduced with mutant ataxin-3 (*B*, $n=7$; *E*, $n=4$), as quantified in *panel C*. Statistical significance was evaluated with Student's *t* test ($*p < 0.05$) comparing caffeine-treated and $A_{2A}R$ inactivated animals with their respective water-drinking control groups.

Figure 6: Synaptotoxicity precedes the neurodegeneration process of MJD. Detection of nerve terminals with synaptic markers: synaptophysin (red) and microtubule-associated protein 2 – MAP-2 (Ab AP20, green). No loss of synapses is observed in the group that was given caffeine whereas loss of synaptophysin and MAP-2 immunoreactivity was observed in the non-treated group 2 weeks post-injection of the lentiviral vectors encoding mutant ataxin-3.

Table 1: DARPP-32 intensity index

100% IR	100.0 ± 3.5	100% IR	100.0 ± 4.1
H ₂ O	43.0 ± 4.1	H ₂ O	39.1 ± 3.1
Caffeine	70.0 ± 2.2**	A _{2A} R KO	54.5 ± 2.2*

Density analysis of DARPP-32 immunoreactivity 12 weeks after mutant ataxin-3 transduction. Caffeine treatment as well as genetic inactivation of A_{2A}R

significantly reduced the loss of this marker (** $p < 0.01$; * $p < 0.05$, respectively).

Note. Data are expressed as indexes of immunoreactivity of the affected striatal regions relative to their corresponding peripheral non-affected striatum (100% IR) [mean±SEM].

Table 2: Synaptophysin and MAP-2 intensity indexes

	Synaptophysin	MAP-2
100% IR	100.0 ± 3.5	100.0 ± 2.6
H ₂ O	65.5 ± 4.6***	74.6 ± 3.0***
Caffeine	89.5 ± 0.6	90.1 ± 2.5

Density analysis of synaptophysin and MAP-2 2 weeks after mutant ataxin-3 transduction. A significant loss of both markers was observed in the water-drinking control group (** $p < 0.001$, one-way ANOVA followed by Dunnett's post-hoc

test). No loss of either marker was observed in the caffeine-treated group.

Note. Data are expressed as indexes of immunoreactivity of the affected striatal regions relative to their corresponding peripheral non-affected striatum (100% IR) [mean±SEM].

Accepted Article




Figure 1: Summary of the time-course of appearance of different morphological features in a lentiviral-based model of Machado-Joseph disease. Loss of synaptic markers and astrogliosis were amongst the most precocious morphological alteration, closely followed by microgliosis and neuronal dysfunction as well as increases of the number of ataxin-3 inclusions, whereas overt neuronal damage occurred later in the development of the disease. Microgliosis would probably be found at later time-points, however, that was not evaluated.

493x183mm (72 x 72 DPI)

Accepted




Figure 2: Caffeine treatment or A2AR genetic depletion decreased cell injury and striatal degeneration. Representative bright-field photomicrographs and immunohistochemical stainings from around the injection site area at 12 weeks post-injection of the viral vectors encoding wild-type or mutant ataxin-3. (A) Coalescence of the internal capsule of the striatum was neither seen in the caffeine-treated group nor in the A2AR KO animals. (B) Cresyl violet-stained sections showed a significant reduction of the number of striatal condensed nuclei upon mutant ataxin-3 transduction in the caffeine-treated group as well as in the A2AR KO group relative to their respective water-drinking groups, as quantified in panel E. (C) A nearly absent loss of neuronal nuclei (NeuN) staining immunoreactivity was seen in the caffeine-treated group as well as in the A2AR KO group. (D) GFAP immunoreactivity showed an increased accumulation of astrocytes (green) replacing neurons after injection of mutant ataxin-3, which was prevented by caffeine consumption. No morphological modifications were detected upon LV-atx3-27Q injections. Statistical significance was evaluated with Student's t test (* $p < 0.05$) comparing both caffeine-drinking and A2AR KO groups with their respective water-drinking wild-type groups upon LV-atx3-72Q injections. 719x793mm (72 x 72 DPI)




Figure 3: Caffeine treatment or A2AR genetic depletion reduced neuronal dysfunction. (A, upper panel) A large DARPP-32 depleted volume was observed 4 weeks after injection of the viral vectors encoding mutant ataxin-3 in the water-drinking group whereas caffeine-drinking mice exhibited a much smaller lesion area at this time-point. This is quantified in panel B as depleted volume of DARPP-32 staining. No loss of DARPP-32 staining was observed upon LV-atx3-27Q injections. (A, lower panel) At higher magnification, 12 weeks exposure to mutated ataxin-3 revealed a clear condensation of the internal capsule, which joined together fiber patches (arrows). This fiber accumulation was not observed in the caffeine-treated animals or in A2AR KO mice. Statistical significance was evaluated with Student's t test ($*p < 0.05$) comparing caffeine-treated ($n=6$) with water-drinking animals ($n=5$).

564x307mm (72 x 72 DPI)

Accept




Figure 4: Caffeine treatment decreased MJD-associated astroglial activation and prevented microglia recruitment. (A) Quantification analysis of GFAP immunoreactivity at 4 weeks post-injection of the viral vectors encoding wild-type or mutant ataxin-3. Caffeine abrogated astrocytic activation ($##p < 0.01$) to the levels induced by wild-type ataxin-3 (internal control). (B) Caffeine consumption attenuated the mutant ataxin-3-induced activation of astrocytes, gauged by enhanced immunoreactivity of Glial Fibrillary Acidic Protein (GFAP, green) at an earlier time point: 2 weeks. (C) No immunoreactivity for activated microglia, CD11b (Ab 5C6, green), was observed 4 weeks after insult in the caffeine-treated group whereas it was present in water-drinking mice. Statistical significance was evaluated with Student's *t* test ($**p < 0.01$) comparing mutant ataxin-3 striatal hemisphere with the contralateral wild-type ataxin-3 hemisphere, and caffeine-drinking with water-drinking groups.

437x793mm (72 x 72 DPI)




Figure 5: Caffeine treatment or A2AR genetic depletion significantly increased the total number of mutant ataxin-3 inclusions. (A) Using anti-ataxin-3 antibody (Ab 1H9), no nuclear inclusions of ataxin-3 were found on both wild-type and A2AR KO animals upon expression of wild-type ataxin-3. (B) A significant increase in the number of mutant ataxin-3 inclusions was observed 8 weeks post-injection of lentiviral vectors encoding mutant ataxin-3 either in caffeine-treated (n=5) or A2AR KO (n=5) mice compared to the respective water-drinking wild-type animals transduced with mutant ataxin-3 (B, n=7; E, n=4), as quantified in panel C. Statistical significance was evaluated with Student's t test (*p < 0.05) comparing caffeine-treated and A2AR inactivated animals with their respective water-drinking control groups.

705x331mm (72 x 72 DPI)

Accepte




Figure 6: Synaptotoxicity precedes the neurodegeneration process of MJD. Detection of nerve terminals with synaptic markers: synaptophysin (red) and microtubule-associated protein 2 – MAP-2 (Ab AP20, green). No loss of synapses is observed in the group that was given caffeine whereas loss of synaptophysin and MAP-2 immunoreactivity was observed in the non-treated group 2 weeks post-injection of the lentiviral vectors encoding mutant ataxin-3.
737x793mm (72 x 72 DPI)

AC